{
    "nct_id": "NCT06488716",
    "official_title": "A Phase Ia/Ib, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors",
    "inclusion_criteria": "* Life expectancy at least 12 weeks\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Adequate hematologic and end-organ function\n* Measurable disease according to Response Evaluation criteria in Solid Tumors (RECIST) Version 1.1\n* Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy\n* Availability of representative tumor specimens required for patients in select cohorts.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Women who are pregnant or breastfeeding\n* Any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, and/or radiotherapy, within 3 weeks prior to initiation of study treatment\n* Active hepatitis B or C or tuberculosis\n* Positive test for human immunodeficiency virus (HIV) infection\n* Acute or chronic active Epstein-Barr virus (EBV) infection at screening\n* Administration of a live, attenuated vaccine (e.g., FluMist) within 4 weeks before first RO7759065 infusion\n* Primary, untreated, or active central nervous system (CNS) metastases\n* Active or history of autoimmune disease or immune deficiency\n* Prior allogeneic stem cell or organ transplantation\n* Any history of a Grade 3 immune-mediated adverse event attributed to prior cancer immunotherapy that resulted in permanent discontinuation of that agent\n* Any history of a Grade 4 immune-mediated adverse event attributed to prior cancer immunotherapy.",
    "miscellaneous_criteria": ""
}